Skip to content

Levothyroxine therapy in sub clinical hypothyroidism

Clinical and Biochemical findings in patients with sub clinical hypothyroidism after treatment with levothyroxine

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT201103156027N1
Enrollment
30
Registered
2011-05-16
Start date
2000-07-31
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Subclinical Hypothyroidism. Subclinical iodine-deficiency hypothyroidism

Interventions

Intervention 1: Levothyroxine in active group with dose adjustment to achieve a serum TSH level between 0.3-3.5 mU/L. Levothyroxine will be used by oral in fasting state for 12 months. Intervention 2
Treatment - Drugs
Placebo
Levothyroxine in active group with dose adjustment to achieve a serum TSH level between 0.3-3.5 mU/L. Levothyroxine will be used by oral in fasting state for 12 months
Placebo in control group, 1 tablet daily by oral root in fasting state for 12 months.

Sponsors

Endocrine and Metabolism research center of shahid Beheshti University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
17 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients with subclinical hypothyroidism Exclusion criteria: Clinical hypothyroidism; Pregnancy; thyroid or Anti-thyroid medication till 1 month before study; history of coronary artery disease and arrhythmia and non cooperative patients

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Thyroid Stimulating Hormone. Timepoint: At the begining, 6 weeks after and then every 3 mo. Method of measurement: IRMA method.

Secondary

MeasureTime frame
Sex hormone binding globulin(SHBG). Timepoint: Baseline and at the end of study. Method of measurement: Radio Immuno Assay.;Creatin Phospho Kinase(CPK). Timepoint: Baseline and at the end of study. Method of measurement: Enzymatic Colorimetry.;Body mass index(BMI). Timepoint: Baseline and at the end of study. Method of measurement: Calculation: Weight(kg)/Height2(m).;Hypothyroidism clinical score. Timepoint: Baseline and at the end of study. Method of measurement: Modified Bilewicz questionnaire.;Psychomotor tests. Timepoint: Baseline and at the end of study. Method of measurement: Coughlan, Ravon and Hospital anexiety depression scales( HADS) tests.;Serum concentration of thyroid antibodies. Timepoint: Baseline and at the end of study. Method of measurement: Radio Immuno Assay(RIA).;Lipids. Timepoint: Baseline and at the end of study. Method of measurement: Enzymatic colorimetry.;Apolipoproteines A and B. Timepoint: Baseline and at the end of study. Method of measurement: Torbidometry.;Paraxonase. Timepoint: Baseline and at the end of study. Method of measurement: Spectrophotometry.;Prolactin. Timepoint: Baseline and at the end of study. Method of measurement: Radio Immuno Assay.;Calcium. Timepoint: Baseline and at the end of study. Method of measurement: Chemical colorimetry.;Alkaline Phosphatase. Timepoint: Baseline and at the end of study. Method of measurement: Chemical colorimetry.;Sodium. Timepoint: Baseline and at the end of study. Method of measurement: Flame Photometry.;Phosphorous. Timepoint: Baseline and at the end of study. Method of measurement: Chemical colorimetry.;Lipoprotein A. Timepoint: Baseline and at the end of study. Method of measurement: Autoanalysis.;Systolic and Diastolic blood pressure. Timepoint: At baselina and at the end of study. Method of measurement: Standard method in Mm/Hg.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSedigheh Moradi

Tehran University of Medical Sciences

s-moradi@tums.ac.ir+98 21 8894 5247

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026